Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: XLRN
CUSIP:

Key Metrics:

Previous Close: $39.50
50 Day Moving Average: $32.23
200 Day Moving Average: $31.93
52-Week Range: $21.93 - $50.86
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -23.13
P/E Growth: 0.00
Market Cap: $1.47B
Outstanding Shares: 37,596,000
Beta: 1.63

Profitability:

Net Margins: -190.41%
Return on Equity: -30.00%
Return on Assets: -25.74%

Debt:

Current Ratio: 9.28%
Quick Ratio: 9.28%

Additional Links:

Companies Related to Acceleron Pharma:

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)

Ratings Breakdown:	9 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$50.86 (25.67% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)

Show:

Date	Firm	Action	Rating	Price Target
8/19/2016	BTIG Research	Initiated Coverage	Buy	$46.00
8/5/2016	FBR & Co	Reiterated Rating	Buy	$63.00
8/5/2016	Morgan Stanley	Reiterated Rating	Buy	$58.00
7/10/2016	Credit Suisse Group AG	Reiterated Rating	Buy
6/12/2016	Leerink Swann	Reiterated Rating	Buy
6/13/2016	Barclays PLC	Boost Price Target	Overweight	$40.00 -> $42.00
6/10/2016	Piper Jaffray Cos.	Reiterated Rating	Buy
4/17/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Buy
2/29/2016	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$45.00 -> $39.00
6/9/2015	Guggenheim	Initiated Coverage	Neutral
3/3/2015	JMP Securities	Boost Price Target	Market Outperform	$52.00 -> $58.00
3/3/2015	Citigroup Inc.	Boost Price Target	Buy	$50.00 -> $52.00

(Data available from 9/27/2014 forward)

Earnings History for Acceleron Pharma (NASDAQ:XLRN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/2/2016
8/4/2016	Q216	($0.50)	($0.59)	$3.77 million	$3.20 million	View	Listen
5/5/2016	Q116	($0.26)	$0.14	$8.70 million	$18.20 million	View	Listen
2/25/2016	Q415	($0.09)	($0.81)	$15.70 million	$3.80 million	View	Listen
11/4/2015	Q315	($0.46)	($0.36)	$4.38 million	$4.16 million	View	Listen
8/6/2015	Q215	($0.49)	($0.32)	$4.23 million	$5.72 million	View	Listen
5/7/2015		($0.43)	($0.45)			View	N/A
3/2/2015	Q414	($0.23)	($0.55)		$3.80 million	View	Listen
11/7/2014		($0.27)	($0.25)			View	N/A
8/12/2014		($0.55)	($0.54)			View	N/A
5/15/2014	Q114	($0.44)	($0.30)	$2.85 million	$3.31 million	View	N/A
2/26/2014	Q413	($0.08)	($0.64)	$13.66 million	$11.50 million	View	N/A
11/6/2013		($0.19)	($5.62)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)

Current Year EPS Consensus Estimate: $-1.60 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.43)	($0.10)	($0.27)
Q2 2016	3	($0.59)	($0.45)	($0.52)
Q3 2016	2	($0.63)	($0.54)	($0.59)
Q4 2016	2	($0.69)	($0.59)	($0.64)

(Data provided by Zacks Investment Research)

Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)

Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 75.55%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/21/2016	John D Quisel	SVP	Sell	45,952	$38.05	$1,748,473.60
9/12/2016	John D Quisel	SVP	Sell	21,438	$32.14	$689,017.32
7/6/2016	John L Knopf	CEO	Sell	100,000	$33.87	$3,387,000.00
7/5/2016	John L Knopf	CEO	Sell	30,501	$33.26	$1,014,463.26
7/5/2016	Steven D Ertel	COO	Sell	32,270	$34.56	$1,115,251.20
7/1/2016	John L Knopf	CEO	Sell	28,022	$34.72	$972,923.84
7/1/2016	Kevin F Mclaughlin	CFO	Sell	25,300	$34.66	$876,898.00
7/1/2016	Matthew L Sherman	EVP	Sell	26,000	$34.74	$903,240.00
7/1/2016	Steven D Ertel	COO	Sell	28,304	$34.77	$984,130.08
5/20/2016	John L Knopf	CEO	Sell	100,000	$33.07	$3,307,000.00
4/7/2016	Matthew L Sherman	EVP	Sell	26,000	$32.00	$832,000.00
4/7/2016	Steven D Ertel	COO	Sell	32,270	$32.00	$1,032,640.00
1/11/2016	Corp /De/ Celgene	Major Shareholder	Buy	800,000	$40.00	$32,000,000.00
10/15/2015	Matthew L. Sherman	EVP	Sell	6,000	$23.28	$139,680.00
10/7/2015	John L. Knopf	CEO	Sell	19,000	$24.38	$463,220.00
10/7/2015	Kevin F. Mclaughlin	CFO	Sell	7,000	$24.38	$170,660.00
9/16/2015	Matthew L. Sherman	EVP	Sell	2,000	$33.24	$66,480.00
9/15/2015	Ravindra Kumar	VP	Sell	33,000	$35.00	$1,155,000.00
9/15/2015	Steven D. Ertel	COO	Sell	2,000	$33.61	$67,220.00
9/14/2015	John D. Quisel	SVP	Sell	5,500	$33.35	$183,425.00
9/8/2015	John L. Knopf	CEO	Sell	19,000	$30.20	$573,800.00
9/8/2015	Kevin F. Mclaughlin	CFO	Sell	6,500	$30.16	$196,040.00
8/18/2015	Matthew L Sherman	EVP	Sell	7,000	$31.13	$217,910.00
8/14/2015	John D Quisel	SVP	Sell	5,500	$30.83	$169,565.00
7/20/2015	Matthew L Sherman	EVP	Sell	6,000	$32.46	$194,760.00
7/15/2015	Steven D Ertel	COO	Sell	2,000	$31.38	$62,760.00
7/14/2015	John D Quisel	SVP	Sell	5,500	$30.00	$165,000.00
7/7/2015	John L Knopf	CEO	Sell	19,000	$29.70	$564,300.00
7/7/2015	Kevin F Mclaughlin	CFO	Sell	7,000	$29.70	$207,900.00
6/18/2015	Matthew L Sherman	EVP	Sell	7,000	$31.54	$220,780.00
6/15/2015	John D Quisel	SVP	Sell	5,500	$31.13	$171,215.00
6/15/2015	Steven D Ertel	COO	Sell	2,000	$31.11	$62,220.00
6/8/2015	John L Knopf	CEO	Sell	19,000	$32.51	$617,690.00
6/8/2015	Kevin F Mclaughlin	CFO	Sell	6,500	$32.49	$211,185.00
5/18/2015	Matthew L Sherman	EVP	Sell	7,000	$32.37	$226,590.00
5/15/2015	Steven D Ertel	COO	Sell	2,000	$31.49	$62,980.00
4/20/2015	Matthew L Sherman	EVP	Sell	5,000	$33.52	$167,600.00
4/15/2015	Steven D Ertel	COO	Sell	2,000	$33.58	$67,160.00
4/7/2015	John L Knopf	CEO	Sell	20,000	$34.87	$697,400.00
4/7/2015	Kevin F Mclaughlin	CFO	Sell	7,000	$34.88	$244,160.00
3/18/2015	Matthew L Sherman	EVP	Sell	6,000	$41.18	$247,080.00
3/16/2015	John D Quisel	SVP	Sell	9,500	$41.00	$389,500.00
3/9/2015	John L Knopf	CEO	Sell	20,000	$40.25	$805,000.00
3/9/2015	Kevin F Mclaughlin	CFO	Sell	6,500	$40.25	$261,625.00
1/20/2015	Matthew L Sherman	SVP	Sell	7,000	$41.64	$291,480.00
1/15/2015	Steven D Ertel	SVP	Sell	2,000	$40.58	$81,160.00
1/12/2015	Kevin F Mclaughlin	CFO	Sell	2,000	$40.66	$81,320.00
1/12/2015	Ravindra Kumar	VP	Sell	1,500	$40.80	$61,200.00
1/7/2015	John L Knopf	CEO	Sell	20,000	$39.62	$792,400.00
1/7/2015	Kevin F Mclaughlin	CFO	Sell	5,000	$39.46	$197,300.00
1/2/2015	Ravindra Kumar	VP	Sell	4,000	$38.46	$153,840.00
1/2/2015	Steven D Ertel	SVP	Sell	5,000	$38.47	$192,350.00
12/23/2014	Edwin M Kania Jr	Director	Sell	54,350	$38.00	$2,065,300.00
12/18/2014	Matthew L Sherman	SVP	Sell	5,000	$40.16	$200,800.00
12/12/2014	John D Quisel	SVP	Sell	4,000	$41.35	$165,400.00
12/9/2014	Jean George	Director	Sell	97,407	$44.90	$4,373,574.30
12/8/2014	John L Knopf	CEO	Sell	20,000	$43.99	$879,800.00
12/8/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$44.02	$440,200.00
12/8/2014	Tom Maniatis	Director	Sell	23,400	$45.00	$1,053,000.00
12/1/2014	Ravindra Kumar	VP	Sell	4,000	$35.88	$143,520.00
12/1/2014	Steven D Ertel	SVP	Sell	7,500	$35.87	$269,025.00
11/18/2014	Matthew L Sherman	SVP	Sell	5,082	$33.76	$171,568.32
11/13/2014	Ravindra Kumar	VP	Sell	16,000	$34.53	$552,480.00
10/28/2014	Tom Maniatis	Director	Sell	23,400	$35.00	$819,000.00
10/8/2014	John L Knopf	CEO	Sell	20,000	$29.71	$594,200.00
10/8/2014	Matthew L Sherman	SVP	Sell	5,082	$29.50	$149,919.00
10/7/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$29.25	$292,500.00
10/1/2014	Ravindra Kumar	VP	Sell	11,000	$29.89	$328,790.00
10/1/2014	Steven D Ertel	SVP	Sell	10,000	$29.66	$296,600.00
9/30/2014	John D Quisel	SVP	Sell	7,000	$30.01	$210,070.00
9/18/2014	Matthew L Sherman	SVP	Sell	5,000	$25.48	$127,400.00
9/12/2014	John D Quisel	SVP	Sell	2,000	$25.43	$50,860.00
9/9/2014	John L Knopf	CEO	Sell	20,000	$24.46	$489,200.00
9/9/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$24.48	$244,800.00
9/8/2014	John L Knopf	CEO	Sell	6,700	$24.92	$166,964.00
9/8/2014	Kevin F Mclaughlin	CFO	Sell	3,300	$24.90	$82,170.00
9/3/2014	Matthew L Sherman	SVP	Sell	5,000	$25.82	$129,100.00
8/18/2014	Matthew L Sherman	SVP	Sell	2,500	$29.62	$74,050.00
8/14/2014	John D Quisel	SVP	Sell	13,000	$29.98	$389,740.00
8/14/2014	John L Knopf	CEO	Sell	17,500	$29.78	$521,150.00
8/14/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$29.78	$297,800.00
8/14/2014	Ravindra Kumar	VP	Sell	9,000	$29.97	$269,730.00
7/18/2014	Matthew L Sherman	SVP	Sell	2,500	$26.22	$65,550.00
7/14/2014	John D Quisel	SVP	Sell	5,000	$29.73	$148,650.00
7/9/2014	Matthew L Sherman	SVP	Sell	7,500	$28.99	$217,425.00
7/7/2014	John L Knopf	CEO	Sell	17,500	$31.74	$555,450.00
7/7/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$31.72	$317,200.00
7/1/2014	Ravindra Kumar	VP	Sell	2,000	$34.10	$68,200.00
7/1/2014	Steven D Ertel	SVP	Sell	10,000	$34.09	$340,900.00
6/26/2014	Jean George	Director	Sell	10,491	$35.01	$367,289.91
6/24/2014	Jean George	Director	Sell	25,477	$35.16	$895,771.32
6/20/2014	Ravindra Kumar	VP	Sell	7,000	$35.00	$245,000.00
6/18/2014	Matthew L Sherman	SVP	Sell	2,500	$34.42	$86,050.00
6/13/2014	John D Quisel	VP	Sell	9,000	$33.94	$305,460.00
6/11/2014	Matthew L Sherman	SVP	Sell	7,500	$33.23	$249,225.00
6/9/2014	John L Knopf	CEO	Sell	15,000	$31.65	$474,750.00
6/9/2014	Kevin F Mclaughlin	CFO	Sell	10,000	$31.65	$316,500.00
5/19/2014	John Knopf	CEO	Sell	15,000	$31.52	$472,800.00
5/19/2014	John Quisel	VP	Sell	9,000	$31.43	$282,870.00
5/19/2014	Steven Ertel	SVP	Sell	10,000	$31.52	$315,200.00
5/5/2014	Corp /De/ Celgene	major shareholder	Buy	1,100,000	$42.86	$47,146,000.00
5/5/2014	Jean George	Director	Sell	215,644	$42.86	$9,242,501.84
4/24/2014	Edwin Kania, Jr.	Director	Sell	1,000,000	$32.05	$32,050,000.00
4/22/2014	Ravindra Kumar	VP	Sell	2,000	$35.86	$71,720.00
4/22/2014	Steven Ertel	SVP	Sell	2,500	$35.87	$89,675.00
1/28/2014	Corp /De/ Celgene	Major Shareholder	Buy	300,000	$50.00	$15,000,000.00
9/24/2013	Corp /De/ Celgene	Major Shareholder	Buy	666,667	$15.00	$10,000,005.00

(Data available from 1/1/2013 forward)

Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)

Date	Headline
	Acceleron Pharma Inc. (NASDAQ:XLRN)'s Expectation Of $251.47 In Sales - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - September 25 at 6:59 PM
	Can Acceleron Pharma Inc. (NASDAQ:XLRN) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - September 24 at 7:13 PM
	Acceleron Pharma Inc (NASDAQ:XLRN)'s SVP - Bus. Dev. - GC & Secretary John Quisel Unloaded 45952 Shares of ... - Post News (NASDAQ:XLRN) www.kentuckypostnews.com - September 23 at 7:31 PM
	EPS Estimate For Acceleron Pharma Inc. (NASDAQ:XLRN) Set At $-0.61 - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - September 21 at 12:01 PM
	ETF’s with exposure to Acceleron Pharma, Inc. : September 20, 2016 (NASDAQ:XLRN) www.capitalcube.com - September 21 at 12:01 PM
	Expected For Acceleron Pharma Inc. (NASDAQ:XLRN) Sales Of $251.47 - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - September 18 at 7:35 PM
	Consensus Take: Acceleron Pharma Inc. (NASDAQ:XLRN) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:XLRN) friscofastball.com - September 17 at 7:32 PM
	Consensus Take: Acceleron Pharma Inc. (NASDAQ:XLRN) Earnings ... - Frisco Fastball (NASDAQ:XLRN) friscofastball.com - September 16 at 7:51 PM
	Could Acceleron Pharma Inc Change Direction After Today's Huge Increase? - Chester News (NASDAQ:XLRN) www.chesterindependent.com - September 15 at 8:19 PM
	Acceleron: A Celgene Partner With A Promising Pipeline - Seeking Alpha (NASDAQ:XLRN) seekingalpha.com - September 13 at 5:46 AM
	Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : September 12, 2016 (NASDAQ:XLRN) www.capitalcube.com - September 12 at 7:38 PM
	ACCELERON PHARMA INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S (NASDAQ:XLRN) biz.yahoo.com - September 12 at 7:38 PM
	Shares Lower Over the Past Quarter: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) www.kentuckypostnews.com - September 11 at 5:37 AM
	Novo As buys $20,569,031 stake in Acceleron Pharma Inc (XLRN ... - National Daily Press (NASDAQ:XLRN) www.nationaldailypress.com - September 9 at 7:48 PM
	Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : September 9, 2016 (NASDAQ:XLRN) www.capitalcube.com - September 9 at 7:48 PM
	ETF’s with exposure to Acceleron Pharma, Inc. : September 8, 2016 (NASDAQ:XLRN) www.capitalcube.com - September 8 at 12:07 PM
	Acceleron Pharma Inc. (NASDAQ:XLRN) Expects To Hit Sales Of $251.47 - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - September 6 at 8:18 PM
	Shares Slipping Lower Over the Past Month: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) www.kentuckypostnews.com - September 1 at 11:34 AM
	Acceleron to Participate in Three Healthcare Investor Conferences in September (NASDAQ:XLRN) www.publicnow.com - September 1 at 11:34 AM
	How is the Crowd Rating Acceleron Pharma Inc. (NASDAQ:XLRN) Shares? - Post News (NASDAQ:XLRN) www.kentuckypostnews.com - August 25 at 5:31 AM
	Analysts See Sales Of $251.47 For Acceleron Pharma Inc. (NASDAQ:XLRN) - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - August 22 at 5:46 AM
	Stock Tracking Lower for the Quarter: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) www.kentuckypostnews.com - August 20 at 7:48 PM
	Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy (NASDAQ:XLRN) www.benzinga.com - August 19 at 11:20 AM
	Earnings Surprise In Focus: Acceleron Pharma Inc. (NASDAQ:XLRN) - Investor Newswire (NASDAQ:XLRN) www.investornewswire.com - August 16 at 8:27 PM
	ACCELERON PHARMA INC Financials (NASDAQ:XLRN) finance.yahoo.com - August 12 at 8:31 PM
	Acceleron Pharma Inc. (XLRN) Drops 7.89% on August 08 - Equities.com (NASDAQ:XLRN) www.equities.com - August 10 at 11:39 AM
	Acceleron Pharma Inc. (XLRN) Drops 7.89% on August 08 (NASDAQ:XLRN) www.equities.com - August 9 at 8:42 PM
	Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:XLRN) www.capitalcube.com - August 5 at 11:28 AM
	Edited Transcript of XLRN earnings conference call or presentation 4-Aug-16 12:00pm GMT (NASDAQ:XLRN) finance.yahoo.com - August 4 at 8:51 PM
	Acceleron Pharma Inc.: Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results (NASDAQ:XLRN) www.twst.com - August 4 at 11:40 AM
	Acceleron reports 2Q loss (NASDAQ:XLRN) sg.finance.yahoo.com - August 4 at 11:40 AM
	Acceleron Pharma Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:XLRN) biz.yahoo.com - August 4 at 11:40 AM
	Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : July 29, 2016 (NASDAQ:XLRN) www.capitalcube.com - July 29 at 8:29 AM
	Acceleron Pharma to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:XLRN) finance.yahoo.com - July 28 at 7:00 AM
	Acceleron Pharma Inc. (XLRN) Jumps 5.45% on July 27 - Equities.com (NASDAQ:XLRN) www.equities.com - July 27 at 8:51 PM
	Acceleron Pharma Appoints Thomas McCourt to its Board of Directors (NASDAQ:XLRN) www.publicnow.com - July 25 at 4:28 PM
	ACCELERON PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:XLRN) biz.yahoo.com - July 25 at 4:17 PM
	Acceleron Pharma Inc. (NASDAQ:XLRN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:XLRN) www.engelwooddaily.com - July 22 at 8:09 PM
	Equity Roundup: Stock Performance Focus on Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph (NASDAQ:XLRN) presstelegraph.com - July 21 at 8:43 PM
	Acceleron Pharma Incorporated (NASDAQ:XLRN) Short Interest Decreased By 4.22% - Consumer Eagle (NASDAQ:XLRN) www.consumereagle.com - July 19 at 9:18 AM
	Share Performance Summary for: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph (NASDAQ:XLRN) presstelegraph.com - July 18 at 5:49 AM
	Shares Experiencing a Downtrend: Acceleron Pharma, Inc. (NASDAQ:XLRN) - TGP (NASDAQ:XLRN) telanaganapress.com - July 16 at 11:32 AM
	Acceleron Pharma Inc. (NASDAQ:XLRN) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:XLRN) www.engelwooddaily.com - July 15 at 7:23 PM
	Analyst Target and Average Rating Watch: Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph (NASDAQ:XLRN) presstelegraph.com - July 15 at 7:23 PM
	Broker Outlook For Acceleron Pharma Inc. (XLRN) - Fiscal Standard (NASDAQ:XLRN) www.fiscalstandard.com - July 15 at 7:23 PM
	What's in Acceleron Pharma Inc After Today's Huge Decline? - Consumer Eagle (NASDAQ:XLRN) www.consumereagle.com - July 14 at 8:37 PM
	Acceleron Pharma Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:XLRN) news.cmlviz.com - July 14 at 8:37 PM
	Acceleron Pharma Inc. (XLRN) Drops 6.35% on July 13 - Equities.com (NASDAQ:XLRN) www.equities.com - July 14 at 8:37 PM
	Option Market: Acceleron Pharma Inc Risk Hits An Elevated Level - CML News (NASDAQ:XLRN) news.cmlviz.com - July 12 at 8:36 PM
	How Analysts Feel About Acceleron Pharma Inc (NASDAQ:XLRN)? - Press Telegraph (NASDAQ:XLRN) presstelegraph.com - July 12 at 8:36 PM